Results 181 to 185 of about 6,976 (185)

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

Lancet, The, 2010
Luca Gianni, Vladimir Semiglazov, Alexey Manikhas   +2 more
exaly  

Hormone receptor status affects locoregional control in HER2-positive breast cancer treated with trastuzumab

Ca-A Cancer Journal for Clinicians, 2012
exaly  

Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group

Journal of Clinical Oncology, 2005
Francesco Cognetti, Ana Lluch, Kenneth J O'byrne   +2 more
exaly  

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

Lancet Oncology, The, 2013
Sandra M Swain, Vladimir Semiglazov, Mario Campone   +2 more
exaly  

Towards personalized treatment for early stage HER2-positive breast cancer

Nature Reviews Clinical Oncology, 2019
Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, Carmine De Angelis   +2 more
exaly